Table 2 Summary of Findings

From: Preclinical extracellular matrix-based treatment strategies for myocardial infarction: a systematic review and meta-analysis

Outcomes

No. of studies (animals)

Pooled effect [95% CI]

Risk of Bias

Inconsistency

Indirectness

Imprecision

Publication Bias

Certainty of the evidence (GRADE)

LVEF

60 studies (1292 animals)

MD 10.9% [8.7%; 13.0%]

Downgrade

Downgrade

No Effect

No Effect

No Effect

Moderatea

FS

38 studies (708 animals)

MD 8.2% [5.6%; 10.9%]

Downgrade

Downgrade

No Effect

No Effect

No Effect

Moderatea

Stroke Volume

12 studies (225 animals)

SMD 0.6 [0.2; 1.0]

Downgrade

Downgrade

No Effect

Downgrade

No Effect

Very Lowb

Infarct Size

52 studies (866 animals)

MD -11.7% [-14.7%; -8.6%]

Downgrade

Downgrade

No Effect

No Effect

No Effect

Moderatea

Wall Thickness

30 studies (758 animals)

SMD 1.2 [0.9; 1.5]

Downgrade

Downgrade

No Effect

No Effect

Downgrade

Lowc

  1. aModerate quality of evidence is due to unknown/unclear risk of bias and serious inconsistency.
  2. bLow quality of evidence is due to unknown/unclear risk of bias, serious inconsistency and imprecision.
  3. cLow quality of evidence is due to unknown/unclear risk of bias, serious inconsistency and publication bias.
  4. LVEF left ventricular ejection fraction, FS fractional shortening, MD mean difference, SMD standardized mean difference, CI confidence interval.